Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent | Zendy

Tomoko Kirihara | Zendy; Takazumi Taniguchi | Zendy; Kenzo Yamamura | Zendy; Ryo Iwamura | Zendy; Kenji Yoneda | Zendy; Noriko OdaniKawabata | Zendy; Atsushi Shimazaki | Zendy; Takeshi Matsugi | Zendy; Naveed Shams | Zendy; Jinzhong Zhang | Zendy

Open Access

Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent

Author(s) -

Tomoko Kirihara,

Takazumi Taniguchi,

Kenzo Yamamura,

Ryo Iwamura,

Kenji Yoneda,

Noriko OdaniKawabata,

Atsushi Shimazaki,

Takeshi Matsugi,

Naveed Shams,

Jinzhong Zhang

Publication year - 2018

Publication title -

investigative ophthalmology and visual science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.935

H-Index - 218

eISSN - 1552-5783

pISSN - 0146-0404

DOI - 10.1167/iovs.17-22745

Subject(s) - prostaglandin e2 receptor , agonist , prostanoid , receptor , pharmacology , intraocular pressure , medicine , prostaglandin , endocrinology , ophthalmology

The objective of this study was to investigate the pharmacologic characteristics of omidenepag isopropyl (OMDI), a compound developed as a novel intraocular pressure (IOP)-lowering agent, with better IOP control and fewer side effects than other prostanoid receptor agonists such as prostaglandin F receptor (FP) agonists.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research